Evidence map›Paper›PMID 41440523›Full record

ArticleMedical sciences (Basel, Switzerland)2025

Prophylactic vs. Intermediate Tinzaparin Dosage for the Thromboprophylaxis of Acutely Ill Medical Patients at High Risk of Venous Thromboembolism.

Karolina Akinosoglou, Stamatia Tsoupra, Ioannis Chandroulis, Eleni Polyzou, Vasiliki Dimakopoulou, Konstantinos Moulakakis, Angelos Perperis, Eleni Karlafti, Elvira Ztriva, Vasileios Patriarcheas and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karolina AkinosoglouDepartment of Medicine, University of Patras, 26504 Rio, Greece.ORCID 0000-0002-4289-9494
Stamatia TsoupraDepartment of Medicine, University of Patras, 26504 Rio, Greece.
Ioannis ChandroulisSchool of Social Sciences, Hellenic Open University, 26331 Patra, Greece.
Eleni PolyzouDepartment of Medicine, University of Patras, 26504 Rio, Greece.
Vasiliki DimakopoulouDepartment of Medicine, University of Patras, 26504 Rio, Greece.
Konstantinos MoulakakisDepartment of Vascular Surgery, University General Hospital "Attikon", 12462 Chaidari, Greece.ORCID 0000-0002-2269-5937
Angelos PerperisDivision of Cardiology, University General Hospital of Patras, 26504 Rio, Greece.ORCID 0000-0003-2290-3940
Eleni KarlaftiFirst Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.ORCID 0000-0001-7094-0338
Elvira ZtrivaFirst Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.ORCID 0000-0002-4013-2767
Vasileios PatriarcheasFirst Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.ORCID 0000-0001-6561-321X
Periklis DavlourosDepartment of Medicine, University of Patras, 26504 Rio, Greece.
Georgia KaiafaFirst Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Christos SavopoulosFirst Propaedeutic Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesVenous thromboembolism (VTE) is the third most common cardiovascular condition, with higher rates among hospitalized patients. The limited efficacy of universal prophylaxis strategies has led to individual VTE risk assessments approaches. The main objective of this study was to assess outcomes in high-risk patients for VTE who receive prophylactic vs. intermediate, weight-adjusted doses of tinzaparin for thromboprophylaxis.

methodsThis was a retrospective study assessing adult patients hospitalized with acute medical disease in a tertiary university hospital from January 2022-2024. Patients were included if found to be at high risk for VTE-as this reflected in Padua Prediction Score (PPS) ≥ 4-and received prophylactic versus intermediate dosage of tinzaparin. Data were collected from patients' files and analyzed using appropriate statistical methods.

resultsIn total, 286 patients were included, of whom 160 received prophylactic and 126 intermediate tinzaparin dosage. The groups were comparable, except for arterial thrombosis history, central venous catheter presence, and median PPS. Patients receiving prophylactic doses exhibited significantly higher mortality rates (20.62 vs. 7.14,

conclusionsThese findings reveal that intermediate tinzaparin dosing is a more effective and safe approach in high-risk for VTE hospitalized patients, emphasizing the need for personalized VTE management.

Indexed as

Fibrinolytic AgentsTinzaparinVenous ThromboembolismAcute DiseaseAdultAgedFemaleHumansLength of StayMaleMiddle AgedRetrospective StudiesRisk FactorsFibrinolytic AgentsTinzaparinintensified prophylaxisintermediate dosageprophylactic dosagethromboembolic eventstinzaparinvenous thromboembolism

Identifiers

PMID41440523
PMCPMC12735053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.